Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early antibiotic discontinuation in pediatric febrile neutropenia
2018-000775-32Phase 4Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Apr 2018
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of piperacillin + tazobactam, amikacin, meropenem, cefepime and vancomycin in febrile neutropenia (FN) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Adverse events attributed to infection. Started Apr 2018; status: active.
02
Drugs
piperacillin + tazobactamamikacinmeropenemcefepimevancomycin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on 2018-000775-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000775-32.